We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
VEGF, VEGFR3, and PDGFRB Protein Expression Is Influenced by RAS Mutations in Medullary Thyroid Carcinoma.
- Authors
Mancikova, Veronika; Inglada-Pérez, Lucía; Curras-Freixes, Maria; de Cubas, Aguirre A.; Gómez, Álvaro; Letón, Rocío; Kersten, Iris; Leandro-García, Luis Javier; Comino-Méndez, Iñaki; Apellaniz-Ruiz, María; Sánchez, Lara; Cascón, Alberto; Sastre-Marcos, Julia; García, Juan F.; Rodríguez-Antona, Cristina; Robledo, Mercedes
- Abstract
Background: Tyrosine kinase inhibitors (TKIs) have achieved remarkable clinical results in medullary thyroid carcinoma (MTC) patients. However, the considerable variability in patient response to treatment with TKIs remains largely unexplained. There is evidence that it could be due, at least in part, to alterations in genes associated with the disease via their effect on the expression of TKI targets. The objective of this study was to evaluate the influence of RAS mutations on the expression levels in MTC tumors of eight key TKI target proteins. Methods: We assessed by immunohistochemistry the expression of EGFR, KIT, MET, PDGFRB, VEGF, VEGFR1, VEGFR2, and VEGFR3 in a series of 84 primary MTC tumors that had previously been molecularly characterized, including 14 RAS-positive, 18 RETM918T-positive, and 24 RETC634-positive tumors, as well as 15 wild-type tumors with no mutations in the RET or RAS genes. Results: In contrast to RET-positive tumors, RAS-positive tumors expressed neither PDGFRB nor MET ( p=0.0060 and 0.047, respectively). Similarly, fewer RAS-positive than RET-related tumors expressed VEGFR3 ( p=0.00062). Finally, wild-type tumors expressed VEGF more often than both RAS- and RET-positive tumors ( p=0.0082 and 0.011, respectively). Conclusions: This is the first study identifying that the expression of TKI targets differs according to the presence of RAS mutations in MTC. This information could potentially be used to select the most beneficial TKI treatment for these patients.
- Subjects
THYROID cancer; GENETIC mutation; PROTEIN-tyrosine kinase inhibitors; IMMUNOHISTOCHEMISTRY; VASCULAR endothelial growth factors; EPIDERMAL growth factor receptors
- Publication
Thyroid, 2014, Vol 24, Issue 8, p1251
- ISSN
1050-7256
- Publication type
Article
- DOI
10.1089/thy.2013.0579